论文部分内容阅读
雷尼替丁是继甲氰咪胍之后的又一新的H_2—受体阻滞剂,为考核对消化性溃疡的治疗效果,我们于1984年5月至1986年10月进行了临床观察,疗效满意,现将结果报告如下: 临床资料本文均经胃镜证实为消化性溃疡300例随机分为雷尼替丁组(A组)与甲氰咪胍组(B组)。A组195例,其中男性182例,女性8例,年龄17～50岁,平均28.62岁。病程0.5～21年,平均5.1年。并发出血、穿孔、幽门梗阻56例,占28.72％,合并各种胃炎、十二指肠球炎145例,占53.85％。B组105例,其中男性96例,女性9例,年龄18～52岁,平均26.57岁,病程0.5～20年,平均4.9年,并发出血、穿孔、幽门梗阻36例,占34.2％,合并各种胃炎、十二指肠球炎48例,
Ranitidine is another new H 2 -receptor blocker after cimetidine. In order to evaluate the therapeutic effect on peptic ulcer, we conducted clinical observation from May 1984 to October 1986, The results are as follows: Clinical data All 300 cases of peptic ulcer confirmed by gastroscopy were randomly divided into ranitidine group (group A) and cimetidine group (group B). A group of 195 cases, including 182 males and 8 females, aged 17 to 50 years, mean 28.62 years. Duration of 0.5 to 21 years, an average of 5.1 years. Hemorrhage, perforation, pyloric obstruction in 56 cases, accounting for 28.72%, with a variety of gastritis, 145 cases of duodenal inflammation, accounting for 53.85%. Group B 105 cases, including 96 males and 9 females, aged 18 to 52 years, mean 26.57 years, duration 0.5 to 20 years, an average of 4.9 years, and blood, perforation, pyloric obstruction in 36 cases, 34.2% 48 kinds of gastritis, duodenal inflammation,